
Our advisory board members are prominent experts from the spectrum of stakeholders involved in real-world evidence in the regulatory and health technology assessment context: regulatory agencies, European patient organisations, HTA, clinical experts, representatives for industry and representatives for payers.
Members
Christine Göppel
GKV-Spitzenverband – National Association of Statutory Health Insurance Funds, Germany
David Wormser
Novartis, Switzerland
Frauke Naumann-Winter
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) – Federal Institute for Drugs and Medical Devices, Germany
Jörg Zinserling
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) – Federal Institute for Drugs and Medical Devices, Germany
Iftekhar Khan
University of Warwick. Health Products Regulatory Authority (HPRA), Ireland
Lukas Enderlein
Roche, Switzerland
Paulo Gonçalves
RD – Portugal (Union of Rare Disease Associations), Portugal
Phil Scordis
UCB Pharma UK, United Kingdom
Roland Linder
Techniker Krankenkasse, Germany
Tala Fakhouri
Food and Drug Administration (FDA), United States of America
Yannis Natsis
European Social Insurance Platform (ESIP), Belgium